- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | CHIMERIC THERAPEUTICS LIMITED: Investor presentation | 2 | ASX | ||
| Mo | CHIMERIC THERAPEUTICS LIMITED: Chimeric to present at NWR Virtual Healthcare Conference | 2 | ASX | ||
| So | CHIMERIC THERAPEUTICS LIMITED: Prospectus | - | ASX | ||
| 18.03. | CHIMERIC THERAPEUTICS LIMITED: Update - Proposed issue of securities - CHM | - | ASX | ||
| 18.03. | CHIMERIC THERAPEUTICS LIMITED: Consolidation/Split - CHM | - | ASX | ||
| 18.03. | CHIMERIC THERAPEUTICS LIMITED: Notice of Extraordinary General Meeting/Proxy Form | - | ASX | ||
| 06.03. | CHIMERIC THERAPEUTICS LIMITED: Letter to Shareholders | 1 | ASX | ||
| 02.03. | Chimeric Therapeutics Secures $1.8 Million Advance on FY26 R&D Tax Incentive | 4 | Finance News Network | ||
| CHIMERIC THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 02.03. | CHIMERIC THERAPEUTICS LIMITED: Chimeric receives $1.8 M advance on FY26 R&D tax incentive | 2 | ASX | ||
| 27.02. | CHIMERIC THERAPEUTICS LIMITED: Half Year Report and Appendix 4D 31 December 2025 | - | ASX | ||
| 26.02. | CHIMERIC THERAPEUTICS LIMITED: Portfolio streamlined - return of CHM CLTX to City of Hope | - | ASX | ||
| 25.02. | CHIMERIC THERAPEUTICS LIMITED: Revised response to ASX Query Letter | 1 | ASX | ||
| 24.02. | CHIMERIC THERAPEUTICS LIMITED: Proposed issue of securities - CHM | - | ASX | ||
| 24.02. | CHIMERIC THERAPEUTICS LIMITED: Update - Proposed issue of securities - CHM | - | ASX | ||
| 24.02. | CHIMERIC THERAPEUTICS LIMITED: Funding and EGM update | - | ASX | ||
| 15.02. | CHIMERIC THERAPEUTICS LIMITED: Initial Director's Interest Notice (BG) | - | ASX | ||
| 15.02. | CHIMERIC THERAPEUTICS LIMITED: Board and management update | - | ASX | ||
| 11.02. | CHIMERIC THERAPEUTICS LIMITED: CHM CDH17 advances to Dose Level 3 | - | ASX | ||
| 27.01. | CHIMERIC THERAPEUTICS LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report | 1 | ASX | ||
| 09.01. | CHIMERIC THERAPEUTICS LIMITED: Change in substantial holding | - | ASX |
1 2 3 Weiter >>
52 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 35,065 | +0,36 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| ADMA BIOLOGICS | 8,280 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Addresses Misleading Short-Seller Report | RAMSEY, N.J. and BOCA RATON, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated... ► Artikel lesen | |
| ARCELLX | 114,64 | +0,10 % | Arcellx legt Zahlen vor - Augenmerk liegt auf Gilead-Übernahme | ||
| MAZE THERAPEUTICS | 31,710 | -0,46 % | Maze Therapeutics: BTIG bestätigt Kaufempfehlung nach positiven Studiendaten | ||
| ENLIVEN THERAPEUTICS | 39,175 | +10,38 % | Enliven Therapeutics stock price target raised to $56 by H.C. Wainwright | ||
| EVOTEC | 4,375 | +0,44 % | EQS-News: Evotec SE: Evotec erhält 10 Mio. $ Meilensteinzahlung von Bristol Myers Squibb im Rahmen der Protein-Degradation-Partnerschaft nach Start einer klinischen Studie | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Evotec erhält 10 Mio. $ Meilensteinzahlung von Bristol Myers Squibb im Rahmen der Protein-Degradation-Partnerschaft nach Start einer... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,270 | -3,84 % | Summit Therapeutics (SMMT) Climbs 15.4% Ahead of Pipeline Q2 Updates | ||
| ERASCA | 15,160 | -5,07 % | Erasca (ERAS) Adds 13%; Soars 310% YTD | ||
| CG ONCOLOGY | 66,60 | +1,20 % | UBS raises CG Oncology stock price target to $90 on trial outlook | ||
| BIONTECH | 75,80 | -0,98 % | Jetzt zuschlagen! Mit BioNTech, Vidac Pharma und Pfizer in die Krebsforschung investieren und Renditen sichern | Die globalen Gesundheitsausgaben explodieren und der Onkologie Sektor verspricht überdurchschnittliche Renditen. Während aufgrund einer immer älter werdenden Bevölkerung die Zahl der Krebsneuerkrankungen... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 302,41 | -2,68 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results | Two new drug applications (NDA) for ulixacaltamide in essential tremor (ET) and for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) have been submitted to the U.S.... ► Artikel lesen | |
| OCUGEN | 1,724 | +0,58 % | Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at 12 months (pPotential 2X treatment benefit compared to 15% and 22% reductions... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 67,19 | +0,58 % | Tarsus Pharmaceuticals, Inc: TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus | IRVINE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced that a $15 million milestone payment due Tarsus has been achieved following regulatory... ► Artikel lesen | |
| BEAM THERAPEUTICS | 23,630 | +2,07 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 46,270 | -3,94 % | Wolfe Research initiates Structure Therapeutics stock rating at Peerperform |
CHIMERIC THERAPEUTICS LIMITED gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CHIMERIC THERAPEUTICS LIMITED finden Sie auf Wallstreet Online.